Researchers identify proteins fueling rare childhood leukemia, revealing new treatment strategy

Indiana University School of Medicine cancer researchers have identified a potential way to use existing, accessible drugs to combat juvenile myelomonocytic leukemia (JMML) by targeting a specific inflammatory pathway. The findings, published in the journal Blood, open the door to more effective treatment options for this rare and aggressive childhood blood cancer, especially for high-risk pediatric patients who currently face limited options.